330 University Avenue 6th floor Toronto, Canada M5G 1R7

Telephone (416) 595-1155 Fax (416) 595-1163

Please Quote

1038-1142 MIS/ac

Our ref.

Your ref.

Writer's Ext. 239

E-mail:

mistewart@sim-mcburney.com

February 19, 2002

**VIA COURIER** 

The Commissioner of Patents and Trademarks Washington, D.C. 20231 United States of America

Dear Sirs:

RE:

U.S. Patent Application No. 09/842,883

Filing Date: April 27, 2001

Applicant: Benjamin Rovinski et al.

Title: IMMUNIZING AGAINST HIV INFECTION

Please find enclosed an Information Disclosure Statement and copies of the references listed therein with respect to each of the references cited in the specification, in the International Search Report received on the corresponding International application. The items indicated by asterisks will follow shortly.

Respectfully submitted,

Michael I. Stewart

Registration No. 24,973

M.I. Stewart/ac Encl.

AFCEIVE CANDO

MICHAEL I. STEWATT
ROGER T. HUGHES OC.
TONI POLSON ASHFAT
JOHN H. WOODLEY
KENNETH D. MCKATT
TIMOTHY M. LOWMAN
STEPHEN M. LANE
ARTHUR B. RENAUD
STEPHEN J. PERRY
PATRICIA A. RAE
DAVID A. RUSTON
L.E. TRENT HORNE
LOLA A. BARTOSZEWICO
THOMAS T. RIEDER

THOMAS T. RIEDER
WARREN J. GALLOWAY
URSULA M. McGUINNESS
ROBERT C. LIANG
ELIZABETH VALENTINA
LESLEY M. MORRISON
GEOFFREY B.C. DE KLEINE

SENIOR CONSULTANTS PETER W. MCBURNEY BRENDA L. BOARDMAN

TECHNICAL ASSISTANTS
KIMBERLY A. MCMANUS, Ph.D.
KAMLEH J. NICOLA, B. Sc. LL.B.
WENDY M. NOSS, B.A., LL.B.
GREGORY W. BANKS, LL.B.
COBY A. B. SCHNEIDER, B.A., LL.B.

## RECEIVED

FEB 2 2 2002

TECH CENTER 1600/2900

FORM R13, 1449

FORM R13, 1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

FEB 2 0 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO. 1038-1142 MIS:ac SERIAL NO. 08/842,883

APPLICANT Benjamin Rovinski et al.

FILING DATE GROUP April 27, 2001 1632

## **U.S. PATENT DOCUMENTS**

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE

## **FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLA	ATION
		WO 99/31250	Jun. 24, 1999	PCT			YES	NO
		WO 91/05864	May 2, 1991	PCT				
		WO 00/50604	Aug. 8, 2000	PCT				
		WO 98/40501	Sept. 17, 1998	PCT				
		WO 01/82962	Nov. 8, 2001	PCT				
OTHER D	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	*	UNAIDS, WHO AIDS epidemic update: December 1999. Genva: World Health     Organisation;1999.						
	*	2. Heyward et al 1998. HIV vaccine development and evaluation: realistic expectations. AIDS Res Hum Retrivir 14:S205-S201.						
	*	3. Haigwood NL and Zolla-Pazner S. 1998. Humoral immunity to HIV, SIV and SHIV. AIDS 12: S121-S132.						
	*	4. Johnson et al. 1998. Cellular immune responses to HIV-1. AIDS 12: S113-S120.						
	*	5. Keefer, M. et al. 1996. AIDS Res Hum Retroviruses. 12:683-693.						
	*	6. Cox W. et al 1993. Virology 198:845-850.						
	*	7. Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz Jr, Sinangil F, Fast PE. 1996. Ann Intern Med Aug 15;125(4):270-279.						
	*	8. Pincus SH, Messer KG, Cole R, Ireland R, VanCott TC, Pinter A, Schwartz DH, Graham BS, Gorse GJ. 1997. J Immunol 1997 Apr 1;158(7):3511-3520.						
	*	9. Fang ZY et al. 1999. J Infect Dis. 180(4):1122-1132.						
EXAMINER	:			DATE CONSIDERED	D:			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

\* Will follow shortly.

FEB 2 0 2002

RECEIVED

FEB 2 2 2002
Sheet 2 of 2

TRADE S. DEPARTMENT OF COMMERCE FORM PTO-1449 PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. SERIAL NO. 1038-1142 MIS:ac 08/842,883 INFORMATION DISCLOSURE STATEMENT BY APPLICANT **APPLICANT** Benjamin Rovinski et al. FILING DATE **GROUP** 

		April 27, 2001	1632				
OTHER DOCU	MENTS (Including Author, Title, Da	ate. Pertinent Pages. Etc.)					
*	10. Rovinski B et al. 1995. AIDS		<b>'-1195</b> .				
*	11. Arp J. et al. 1999. Viral Immunolgy 12(4):281-296.						
*	12. Zolka-Pazner et al. J. Virology, Vol. 72:1052-1059, 1998.						
*	13. Karin M and Richards RI. Human metallothionein genes – primary structure of the metallothionein-II gene and a related processed gene. Nature 1982;299:797-802.						
	14. Sambrook J et al. Molecular Cloning A Laboratory Manual, Second Ed.: Cold Spring Harbour Laboratory Press. 1989.						
	15. Haynes JR. et al. Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines. AIDS Res Hum Retroviruses 1991; 7:17-27.						
*	16. Persson R, et al. Modifications of HIV-1 Retrovirus-like Particles to Enhance Safety and Immunogenicity. Biologicals 1998, 26(4); 255-265.						
*	nsformation of mammalian cells of the SV40 early region promo						
*	1982;1: 327-341 18. Graham, B.S. et al. 1993, J. Infection Des. 167:533-537.						
	19. Tartaglia, J. et al., 1992, Virol	ogy, 188: 219-232.					
*	20. Piccini, A. et al., 1987, Methods in Enzymology 153: 545-563.						
	21. Caver T. E. et al "A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, Vol. 17, no. 11-12, 1999-03, pp. 1567-1572, XP004158286						
	22. Evans, T.G. et al.: "A Canarypox vaccine expressing multiple human immunodefiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers." J. Infect. Diseases, vol. 180, 1999, pp. 290-298, XP002185651.						
		<del>-</del>					
EXAMINER:		DATE CONSIDERED:					